Morgan Stanley Applied Therapeutics Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,194,052 shares of APLT stock, worth $13.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,194,052

Previous 53,623 5856.5%

Holding current value

$13.7 Million

Previous $179,000 12033.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.25 - $7.4 $7.07 Million - $23.2 Million	3,140,429 Added 5856.5%	3,194,052 $21.7 Million
Q4 2023 Feb 13, 2024	BUY	$1.84 - $3.35 $4,143 - $7,544	2,252 Added 4.38%	53,623 $179,000
Q3 2023 Nov 15, 2023	SELL	$1.26 - $2.77 $4,224 - $9,287	-3,353 Reduced 6.13%	51,371 $127,000
Q2 2023 Aug 14, 2023	BUY	$0.77 - $1.8 $41,986 - $98,150	54,528 Added 27820.41%	54,724 $70,000
Q1 2023 May 15, 2023	SELL	$0.75 - $1.21 $3,213 - $5,183	-4,284 Reduced 95.63%	196 $0

Q4 2022 Feb 14, 2023	SELL	$0.65 - $1.12 $10,138 - $17,468	-15,597 Reduced 77.69%	4,480 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.86 - $1.55 $76,986 - $138,754	-89,519 Reduced 81.68%	20,077 $18,000
Q2 2022 Oct 27, 2022	BUY	$0.76 - $2.64 $67,769 - $235,408	89,170 Added 436.55%	109,596 $103,000
Q2 2022 Aug 15, 2022	BUY	$0.76 - $2.64 $67,769 - $235,408	89,170 Added 436.55%	109,596 $103,000
Q1 2022 Oct 27, 2022	SELL	$1.48 - $6.22 $131,971 - $554,637	-89,170 Reduced 81.36%	20,426 $43,000
Q1 2022 May 13, 2022	BUY	$1.48 - $6.22 $2,393 - $10,057	1,617 Added 8.6%	20,426 $43,000
Q4 2021 Feb 14, 2022	BUY	$8.77 - $18.29 $36,939 - $77,037	4,212 Added 28.86%	18,809 $168,000
Q3 2021 Nov 15, 2021	BUY	$13.54 - $22.06 $197,643 - $322,009	14,597 New	14,597 $242,000

Others Institutions Holding APLT

# of Institutions

100

Shares Held

94M

Call Options Held

5.83M

Put Options Held

231K

View Full List

About Applied Therapeutics Inc.

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $206M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

More about APLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account